Literature DB >> 10233993

Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

P F Zhang1, X Chen, D W Fu, J B Margolick, G V Quinnan.   

Abstract

To test the hypothesis that changing neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1) during chronic infection were a response to emergence of neutralization escape mutants, we cloned expressed and characterized envelope clones from patients in the Multicenter AIDS Cohort Study (MACS). Pseudotyped HIV-1 envelope clones obtained from differing time points were assessed for sensitivity to neutralization by using sera from different times from the same and different patients. Clones from early and late time points during chronic infection had similar neutralization sensitivity, and neutralizing antibody responses cross-reacted with early, late, and heterologous envelopes. The potential for broadly effective HIV-1 immunization is supported.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10233993      PMCID： PMC112575     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  HIV-1 intrapatient sequence diversity in the immunogenic V3 region.

Authors:  B Korber; S Wolinsky; B Haynes; K Kunstman; R Levy; M Furtado; P Otto; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-08       Impact factor: 2.205

2.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Authors:  B A Watkins; S Buge; K Aldrich; A E Davis; J Robinson; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation.

Authors:  H C Liou; W C Sha; M L Scott; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

5.  Preparation and characterization of human HIV type 1 neutralizing reference sera.

Authors:  L K Vujcic; G V Quinnan
Journal:  AIDS Res Hum Retroviruses       Date:  1995-07       Impact factor: 2.205

6.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Authors:  J R Mascola; J Louwagie; F E McCutchan; C L Fischer; P A Hegerich; K F Wagner; A K Fowler; J G McNeil; D S Burke
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

7.  Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.

Authors:  J P Langedijk; G Zwart; J Goudsmit; R H Meloen
Journal:  AIDS Res Hum Retroviruses       Date:  1995-10       Impact factor: 2.205

8.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Development of HIV-1 group-specific neutralizing antibodies after seroconversion.

Authors:  A McKnight; P R Clapham; J Goudsmit; R Cheingsong-Popov; J N Weber; R A Weiss
Journal:  AIDS       Date:  1992-08       Impact factor: 4.177

10.  Immune escape and tropism of HIV.

Authors:  A McKnight; P R Clapham
Journal:  Trends Microbiol       Date:  1995-09       Impact factor: 17.079
View more
  18 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

5.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

7.  Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.

Authors:  Tiffany N Grooms; Hung R Vuong; Kevin M Tyo; Danial A Malik; Lee B Sims; Carli P Whittington; Kenneth E Palmer; Nobuyuki Matoba; Jill M Steinbach-Rankins
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.

Authors:  Ming Dong; Peng Fei Zhang; Franziska Grieder; James Lee; Govindaraj Krishnamurthy; Thomas VanCott; Christopher Broder; Victoria R Polonis; Xiao-Fang Yu; Yiming Shao; Dennis Faix; Patricia Valente; Gerald V Quinnan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Widespread adaptive evolution in the human immunodeficiency virus type 1 genome.

Authors:  Wa Yang; Joseph P Bielawski; Ziheng Yang
Journal:  J Mol Evol       Date:  2003-08       Impact factor: 2.395

10.  Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Authors:  Krystal Teasley Hamorsky; Tiffany W Grooms-Williams; Adam S Husk; Lauren J Bennett; Kenneth E Palmer; Nobuyuki Matoba
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.